Skip to main content
Equibles
TRAW logo

TRAW · Traws Pharma, Inc. · Holdings

Track TRAW — free

Use TRAW with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRAW.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.37 +0.02 (+7.30%) At close · Oct 27 Q2 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.21M
Shares
15.37M
Volume · Oct 27 150.58K Avg daily vol (3M) 568.6K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Use institutional holdings through the 13F API or MCP → See every holder of TRAW: 13F, 13D and 13G, insiders and funds →
The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 34
Total Value: $6,046,285
Total Shares: 6,181,073

Institutional Ownership Trend

27 quarters

Holder Concentration

Across 35 13F filers
Top Holder
16.7%
Sep 2023 → Jun 2026 · range 16.7% – 93.7%
of institutional value
Top 5
60.5%
Sep 2023 → Jun 2026 · range 60.5% – 99.8%
of institutional value
Top 10
88.0%
Sep 2023 → Jun 2026 · range 88.0% – 100.0%
of institutional value
HHI
960
Sep 2023 → Jun 2026 · range 960 – 8,796
Broadly held

Who Holds TRAW

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 35 filers, like-for-like change +70.8%; actively managed books +64.3%; index-like books +179.8%.

Holder type Share Filers Change
Registered adviser 83.8% 14 +67.0%
Exempt adviser 6.4% 1 new
Bank 1.1% 4 +130.3%
Non-US 0.3% 2 +12591.4%
Holding company 0.2% 3 -24.1%
Broker-dealer 0.0% 0 —
Unknown 8.2% 11 +7.2%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Conviction and Crowding

34 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
0
0.000% of filers hold it in their top 10
Mar 31, 2026: 0
Holders above 5%
0
median weight 0.000%
Mar 31, 2026: 0
Crowding
36.7%
of shares outstanding, 89th percentile
Mar 31, 2026: 41.9%
Private-fund advisers
33.9%
of shares outstanding
Institutional ownership
40.6%
42.6% of the estimated free float
Top 10 holders
88.8%
of 13F shares, Herfindahl 0.103
Active holders
+63.5%
like-for-like share change of active filers
5% stakes on record
7
2 13D, 5 13G (3 institutional, 2 passive, 0 exempt)
How long holders have held it value-weighted 4.2 quarters
Under 1 year 58.8% 1 to 3 years 41.2% 3 years or more 0.056% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$1.94
estimated per share
Mar 31, 2026: $2.63
Quarter-end price
$0.84
implied by 13F values
Estimated gain or loss
-56.7%
price against the estimated cost
Estimated at a loss
100.0%
of costed 13F value

Estimated cost covers 74.0% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies TRAW's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 PMN ProMIS Neurosciences Inc. 3
2 PRQR ProQR Therapeutics N.V. 4
3 IMTX Immatics N.V. 3
4 EPRX Eupraxia Pharmaceuticals Inc. 3
5 TRAX First Tracks Biotherapeutics, Inc. 3
6 OVID Ovid Therapeutics Inc. 3
7 CLYM Climb Bio, Inc. 3
8 AVTX Avalo Therapeutics, Inc. 4
9 PALI Palisade Bio, Inc. 3
10 CTMX CytomX Therapeutics, Inc. 3

Shareholder Targets

13F filers that own its peers but not TRAW, quarter ended Jun 30, 2026

Found through its holder-overlap peers: PMN, PRQR, IMTX, EPRX, TRAX, OVID, CLYM, AVTX, PALI, CTMX, CLDX, COGT. 518 filers in all.

# Filer In peers
1 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $580,855,946 10 held
2 PRICE T ROWE ASSOCIATES INC /MD/ Registered adviser, Diversified active $412,595,303 9 held
3 Jupiter Topco LLC Unknown, Diversified active $381,696,474 8 held
4 VANGUARD PORTFOLIO MANAGEMENT LLC Registered adviser, Diversified active $375,344,147 8 held
5 TCG Crossover Management, LLC Unknown, Diversified active $301,876,566 3 held
6 Deep Track Capital, LP Adviser, Diversified active $264,475,827 4 held
7 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $226,557,915 1 held
8 RTW INVESTMENTS, LP Registered adviser, Diversified active $223,737,874 3 held
9 Fairmount Funds Management LLC Registered adviser, Concentrated $212,982,276 1 held
10 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $208,981,248 4 held

Fund Ownership of TRAW by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 2.51% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.36% 55,646
Index ETFs 2.15% 330,049
Active ETFs 0.00% 0
Active funds 0.00% 11
Unclassified 0.00% 0
All registered funds 2.51% 385,706
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Holder type: Registered adviser 13 Exempt adviser 1 Bank 4 Non-US 2 Holding company 3 Unknown 11
Showing 35 of 35
All Common Calls Puts
Export CSV
Holder Value (USD) % of 13F Shares Open
ORBIMED ADVISORS LLC $1,010,738 16.72% 1,203,260
GTS SECURITIES LLC ONTX $870,914 14.40% 24,616
Ally Bridge Group (NY) LLC $660,438 10.92% 786,236
ADAGE CAPITAL PARTNERS GP, L.L.C. $613,200 10.14% 730,000
ADAR1 Capital Management, LLC $502,092 8.30% 597,729
Lynx1 Capital Management LP $469,954 7.77% 559,470
Ikarian Capital, LLC $401,639 6.64% 478,142
SPHERA FUNDS MANAGEMENT LTD. $334,728 5.54% 398,486
VANGUARD CAPITAL MANAGEMENT LLC $277,241 4.59% 330,049
JANE STREET GROUP, LLC $181,444 3.00% 216,006
Alyeska Investment Group, L.P. $138,075 2.28% 164,376
BOOTHBAY FUND MANAGEMENT, LLC $112,506 1.86% 133,936
GEODE CAPITAL MANAGEMENT, LLC $93,546 1.55% 111,365
HRT FINANCIAL LP $76,624 1.27% 91,220
Kynam Capital Management, LP $70,896 1.17% 84,400
Dauntless Investment Group, LLC $67,682 1.12% 80,574
VANGUARD FIDUCIARY TRUST CO $45,789 0.76% 54,511
NORTHERN TRUST CORP $31,461 0.52% 37,454
STATE STREET CORP $21,673 0.36% 25,802
XTX Topco Ltd $15,197 0.25% 18,092
SG Americas Securities, LLC $12,200 0.20% 14,524
Virtu Financial LLC $10,566 0.17% 12,579
BlackRock, Inc. $8,350 0.14% 9,941
UBS Group AG ONTX $4,493 0.07% 127
Tower Research Capital LLC (TRC) $4,319 0.07% 5,142
HUNTINGTON NATIONAL BANK $3,927 0.06% 4,676
UBS Group AG $2,897 0.05% 3,451
BARCLAYS PLC $1,635 0.03% 1,947
SBI Securities Co., Ltd. $1,023 0.02% 1,723
Federation des caisses Desjardins du Quebec $420 0.01% 500
MORGAN STANLEY $392 0.01% 468
Vanguard Global Advisers, LLC $220 0.00% 262
HARBOUR INVESTMENTS, INC. $4 0.00% 5
FMR LLC $1 0.00% 2
JONES FINANCIAL COMPANIES LLLP $1 0.00% 2
Key facts CIK 1130598 CUSIP 68232V884 13F (30d) 1 filings 1 filers Visit website